尿激酶与阿替普酶治疗脑梗死的临床疗效对比  

Comparison of Clinical Efficacy Between Urokinase and Alteplase in Treatment of Cerebral Infarction

作　　者：廖跃斌[1] 张立仲[1] LIAO Yuebin;ZHANG Lizhong(Department of Emergency,Meizhou Municipal People's Hospital,Meizhou Guangdong 514031,China)

机构地区：[1]梅州市人民医院急诊科,广东梅州514031

出　　处：《中国继续医学教育》2020年第18期150-152,共3页China Continuing Medical Education

摘　　要：目的对比尿激酶与阿替普酶治疗急性脑梗死(ACI)临床疗效。方法在医院收治的ACI患者中选取60例,纳入时间为2016年6月-2018年10月,随机均衡分为两组,每组30例,治疗时,对照组选择尿激酶,观察组选择阿替普酶,对比治疗的效果。结果治疗前,两组NIHSS评分、mRS评分、QOL-C30评分对比,统计学无意义(P>0.05);经治疗7 d后,NIHSS评分、mRS评分、QOL-C30评分对比,观察组数据均优于对照组(P<0.05),但两组总有效率、发生不良反应率比较差异无统计学意义(P>0.05)。结论ACI治疗时选择阿替普酶,与尿激酶相比,疗效好,可更好地改善患者的神经功能缺损症状,提高生活质量。Objective To compare the clinical effects of urokinase and alteplase in the treatment of acute cerebral infarction(ACI).Methods From June 2016 to October 2018,60 ACI patients admitted to our hospital were randomly and evenly divided into two groups,with 30 cases in each group.During treatment,urokinase was selected in the control group and alteplase was selected in the observation group to compare the therapeutic effects.Results Before treatment,the comparison of NIHSS score,mRS score and QOL-C30 score between the two groups was statistically insignificant(P>0.05).After 7 days of treatment,the NIHSS score,mRS score,and QOL-C30 score were compared.The observation group data were better than the control group(P<0.05),but there was no statistically significant difference in the total effective rate and the probability of adverse reactions between the two groups.(P>0.05).Conclusion Alteplase is selected during ACI treatment.Compared with urokinase,it has a better curative effect,which can better improve the patients'neurological deficit symptoms and improve the quality of life.

关 键 词：尿激酶 阿替普酶 脑梗死 神经功能 不良反应 神经缺损 

分 类 号：R575[医药卫生—消化系统]